Valeant Pharmaceuticals closes deal on Bausch + Lomb

LAVAL, Quebec — Valeant Pharmaceuticals on Tuesday announced it has completed its previously announced acquisition of Bausch + Lomb.  

Bausch + Lomb is a global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and Victus.

Valeant started the process in May, when it announced the all-cash $8.7 billion acquisition. The move will make Valeant one of the leaders worldwide across both dermatology and eye health, the company said. 

Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

Login or Register to post a comment.